AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24194293
Drug: Nelfinavir (NFV)
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelfinavir (NFV) 1,250 mg bid concurrent with temozolomide (TMZ) 150-200 mg/m(2) and radiotherapy (6,000 cGy)
Trial: 24194293
Drug: Nelfinavir (NFV)
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelfinavir (NFV) 625 mg bid concurrent with temozolomide (TMZ) and radiotherapy
Trial: 20810596
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics plus cognitive-behavioral therapy
Trial: 20810596
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics alone
Trial: 15250203
Drug: Chuankezhi injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chuankezhi injection
Trial: 15250203
Drug: Ginkgo injection
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo injection
Trial: 12431243
Drug: Oral taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral taurine (1000 mg d(-1))
Trial: 8137333
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with 26 vitamins and minerals for 6 years
Trial: 477258
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium chloride (50 mmol three times daily for 3 days)
Trial: 477258
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium chloride (50 mmol in 50 ml over 22 min)
Trial: 21304064
Drug: Lean subjects
RxNorm normalized name: Lophophytum leandrii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean subjects (L)
Trial: 15262693
Drug: MT‐1 (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT‐1 (0.08 mg/kg per day subcutaneously) with UV‐B light (3 times the minimal erythema dose) for 10 days
Trial: 15262693
Drug: MT‐1 (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT‐1 (0.16 mg/kg per day) with UV‐B radiation (0.25‐0.75 MED) for 10 days
Trial: 15262693
Drug: MT‐1 (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT‐1 (0.16 mg/kg) for 5 days per week for 4 weeks with sunlight
Trial: 7807244
Drug: Teaching intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teaching intervention on pressure ulcer risk, assessment, and treatment
Trial: 30832665
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment voucher
Trial: 27159290
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (20 mL Exparel + 20 mL 0.9% saline)
Trial: 27159290
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine hydrochloride (20 mL 0.5% bupivacaine HCl + 20 mL 0.9% saline)
Trial: 16814935
Drug: Alcohol use
RxNorm normalized name: Vorvida Problematic Alcohol Use Support Software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol use during tobacco cessation treatment
Trial: 15701778
Drug: Flex-dose group
RxNorm normalized name: Ed Flex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flex-dose group (topiramate with adjustable AED cotherapy)
Trial: 15701778
Drug: Fixed-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose group (topiramate with fixed AED cotherapy)
Trial: 9456212
Drug: Titration search
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titration search procedure
Trial: 938161
Drug: C3 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C3 treatment
Trial: 28929695
Drug: Astragali Radix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragali Radix group 1 (10 g•d⁻¹)
Trial: 28929695
Drug: Astragali Radix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragali Radix group 2 (5 g•d⁻¹)
Trial: 28929695
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional medical treatment)
Trial: 9399755
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.i.d., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d. (RAC)
Trial: 9399755
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.i.d., metronidazole 250 mg t.i.d., and tetracycline 500 mg t.i.d. (RMT)
Trial: 2907080
Drug: Propranolol (PROP)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (PROP) 80 mg b.i.d.
Trial: 2907080
Drug: Atenolol (ATEN)
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol (ATEN) 100 mg o.d.
Trial: 21608219
Drug: Tongxinluo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxinluo Capsule (TXL)
Trial: 10653873
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of adjuvant chemotherapy within 20 days after surgery (599 patients, 84 with ER-absent tumors)
Trial: 10653873
Drug: Conventional initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Conventional initiation of adjuvant chemotherapy 21 to 86 days after surgery (1,189 patients, 142 with ER-absent tumors)
Trial: 10653873
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of chemotherapy for ER-expressing tumors (1,562 patients)
Trial: 3302842
Drug: Relaxation training
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation training (6 weekly sessions of 75 min duration in progressive relaxation)
Trial: 30646281
Drug: Standardized program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized program for identification, assessment, and treatment of osteoporosis led by a trained coordinating nurse.
Trial: 23990572
Drug: Efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (600 mg/d) plus standard antituberculosis treatment (rifampicin and isoniazid)
Trial: 23990572
Drug: Efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (600 mg/d) alone
Trial: 23990572
Drug: Standard antituberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antituberculosis treatment (rifampicin and isoniazid)
Trial: 19166443
Drug: ERN/LRPT 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERN/LRPT 2 g
Trial: 12373599
Drug: Analogy of
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analogy of 'a computer will perform the equivalent of tossing a coin to allocate you to one of two methods of treatment'
Trial: 2675752
Drug: Norfloxacin, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin, 200 mg orally daily at bedtime
Trial: 174244
Drug: DBcAMP administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBcAMP administered intravenously at 10 mg/min for 20 min
Trial: 174244
Drug: DBcAMP administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBcAMP administered intravenously at 20 mg/min for 20 min
Trial: 7362696
Drug: Oxandrolone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (7.5 mg/day)
Trial: 7362696
Drug: PAS-C (6-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAS-C (6-8 g/day)
Trial: 7362696
Drug: Colestipol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol (20 g/day)
Trial: 25067799
Drug: Baroreflex activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreflex activation therapy (BAT) for 6 months
Trial: 23069315
Drug: lamivudine and
RxNorm normalized name: lamivudine and abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamivudine and adefovir diprivoxil combination therapy (LA)
Trial: 23069315
Drug: lamivudine alone
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine alone (L)
Trial: 23069315
Drug: lamivudine and
RxNorm normalized name: lamivudine and abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamivudine and adefovir diprivoxil combination therapy (LA) followed by adefovir monotherapy
Trial: 19545976
Drug: Risperidone (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1.5 mg), Perphenazine (8 mg), Ziprasidone (40 mg), Quetiapine (200 mg)
Trial: 15138710
Drug: Imatinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 200 mg alone
Trial: 15138710
Drug: Imatinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 200 mg with ketoconazole 400 mg
Trial: 9698972
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug (sham second drug)
Trial: 2547464
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate given together and 30 min after diflunisal tablets
Trial: 2547464
Drug: Diflunisal (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (oral administration)
Trial: 2547464
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of diflunisal
Trial: 1103896
Drug: Verapamil, 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil, 240 mg orally
Trial: 31339232
Drug: Autonomic regulation
RxNorm normalized name: AUTONOMIC MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autonomic regulation therapy added to guideline-directed medical therapy (GDMT)
Trial: 31339232
Drug: Beta-blocker doses
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker doses in ANTHEM-HF
Trial: 31339232
Drug: Beta-blocker doses
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker doses in ANTHEM-HF vs. PARADIGM-HF
Trial: 24035673
Drug: Guided internet-delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet-delivered cognitive behaviour therapy (ICBT)
Trial: 24035673
Drug: Group-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based cognitive behaviour therapy (CBT)
Trial: 22187792
Drug: Clonidine 0.5
RxNorm normalized name: apraclonidine 0.5 % Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.5 ml (75 microg) plus 5 ml 0.25% bupivacaine
Trial: 22187792
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml 0.25% bupivacaine plus 0.5 ml of normal saline (NS)
Trial: 19001516
Drug: Intralipid (20%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (20%, 40 ml/h) plus heparin (250 units/h)
Trial: 19001516
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (40 ml/h) plus heparin (250 units/h)
Trial: 8027497
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate eye drops (Opticrom 2%) used regularly (four times daily)
Trial: 8027497
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate eye drops (Opticrom 2%) used as needed (up to four times daily)
Trial: 952693
Drug: 1.5% etiodocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% etiodocaine HCl 20 ml with adrenaline 5 mug/ml
Trial: 952693
Drug: 0.75% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% bupivacaine HCl 20 ml with adrenaline 5 mug/ml
Trial: 9266456
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg BSH/kg body weight administered 2.5‐16 hrs prior to tumor removal
Trial: 3546611
Drug: DES-CEF (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DES-CEF (cyclophosphamide, 600 mg/m2; DES, 1 mg orally on days 5, 6, and 7; epidoxorubicin, 60 mg/m2; 5-fluorouracil, 600 mg/m2)
Trial: 3546611
Drug: CEF (cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF (cyclophosphamide, 600 mg/m2; epidoxorubicin, 60 mg/m2; 5-fluorouracil, 600 mg/m2)
Trial: 30284429
Drug: Medication (conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (conservative therapy)
Trial: 25381789
Drug: Self-management program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management program using goal setting based on G-AP
Trial: 22795205
Drug: Cognitive‐behavioral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavioral therapy (20 individual sessions)
Trial: 17574801
Drug: Standard methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methadone treatment (control group, n = 49)
Trial: 15850918
Drug: High-dose regions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose regions (V100 >= 90%)
Trial: 15850918
Drug: High-dose regions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose regions (V100 < 90%)
Trial: 12825092
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral dose of caffeine freebase
Trial: 8762218
Drug: enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 20 mg-hydrochlorothiazide 12.5 mg
Trial: 8762218
Drug: enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 20 mg-nifedipine SL 20 mg x 2
Trial: 1342582
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol maleate with 2% pilocarpine hydrochloride given twice a day
Trial: 1342582
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol with 4% pilocarpine given twice a day
Trial: 31612981
Drug: Contraceptive methods
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive methods (various types including contraceptive pill, withdrawal, breast-feeding)
Trial: 31612981
Drug: Age, duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, duration of marriage, and high monthly income
Trial: 24823280
Drug: Metformin-based OAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin-based OAD
Trial: 23659733
Drug: Continued warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued warfarin treatment
Trial: 23659733
Drug: Bridging therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging therapy with heparin
Trial: 18444052
Drug: Lovaas's treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovaas's treatment
Trial: 15882879
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg per day p.o. for 1 week pre-operatively)
Trial: 25267738
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) continued for an additional 6 months (group A1)
Trial: 25267738
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) discontinued (group A2)
Trial: 19194341
Drug: Drospirenone 2
RxNorm normalized name: drospirenone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 2 mg/estradiol 1 mg (group 1; n = 15)
Trial: 19194341
Drug: Norethisterone acetate
RxNorm normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethisterone acetate 0.5 mg/estradiol 1 mg (group 2; n = 15)
Trial: 16014067
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose dalteparin (bolus of 40 IU/kg body weight)
Trial: 16014067
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose dalteparin
Trial: 16014067
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral anticoagulation (phenprocoumon)
Trial: 10618886
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) at a dose of 0.7 IU/kg per week for 12 months
Trial: 7605770
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg hyperbaric 0.75% bupivacaine in 8.25% dextrose
Trial: 7605770
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg hyperbaric 0.75% bupivacaine in 8.25% dextrose
Trial: 1664824
Drug: Temafloxacin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin (high dose)
Trial: 25032141
Drug: No sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sedative medication (Control)
Trial: 20636634
Drug: Valnoctamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valnoctamide (600 mg/day increased to 1200 mg after four days)
Trial: 18198637
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of propofol (Pro I)
Trial: 9871427
Drug: Moxonidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine treatment after 3, 5, and 11 weeks
Trial: 9871427
Drug: Moxonidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine treatment after 8 weeks
Trial: 2694343
Drug: Furazolidone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furazolidone (7.5 mg/kg/day for 5 days)
Trial: 2694343
Drug: Trimethoprim-sulfamethoxazole (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (8 mg/40 mg/kg/day for 5 days)
Trial: 38261
Drug: Clobazam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (40 mg daily, increased to 80 mg daily by day 3 if well tolerated)
Trial: 31676280
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (CMT)
Trial: 28272220
Drug: Sertraline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline + Doxazosin (4mg + 50mg)
Trial: 26299324
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h continuous infusion)
Trial: 24060577
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with detectable circulating tumor cells (CTCs)
Trial: 24060577
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy without detectable circulating tumor cells (CTCs)
Trial: 21119518
Drug: Low-flow inhalational
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow inhalational anaesthesia (1 l min(‐1) O2 + 0.5 l min(‐1) N2O + desflurane)
Trial: 21119518
Drug: High-flow inhalational
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow inhalational anaesthesia (3 l min(‐1) O2 + 1.5 l min(‐1) N2O + desflurane)
Trial: 18069178
Drug: 2% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% w/w minocycline gel (Dentomycin)
Trial: 29998359
Drug: Neuromuscular blocker
RxNorm normalized name: Neuromuscular blocker product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blocker (NM) group
Trial: 29998359
Drug: Non-neuromuscular blocker
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-neuromuscular blocker (non-NM) group
Trial: 18463891
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride drink with 1 mmol/l sodium concentration
Trial: 18463891
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride drink with 31 mmol/l sodium concentration
Trial: 18463891
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride drink with 40 mmol/l sodium concentration
Trial: 18463891
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride drink with 50 mmol/l sodium concentration
Trial: 17138196
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (0.3 mg) and postoperative PCA intravenous morphine
Trial: 14627850
Drug: Coralline hydroxyapatite
RxNorm normalized name: Corallina officinalis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coralline hydroxyapatite implants